Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design
Why the study?
Does clopidogrel plus aspirin reduce the composite of new ischemic vascular events in patients with transient ischemic attack or minor ischemic stroke compared with aspirin alone?
Population
Patients with transient ischemic attack or minor ischemic stroke
Comparison
Clopidogrel plus open-label aspirin 50–325 mg/day vs Matching placebo plus open-label aspirin 50–325…
Design
RCT, randomized, double-blind
Follow-up
90 days
Authors
Discussion
Loading...
Member takes
Implication
POINT RCT design tests dual antiplatelet therapy post-TIA; leaves open whether clopidogrel plus aspirin reduces ischemic events versus aspirin alone.
Structured PICO
Does clopidogrel plus aspirin reduce the composite of new ischemic vascular events in patients with transient ischemic attack or minor ischemic stroke compared with aspirin alone?
P
Population
Patients with transient ischemic attack or minor ischemic stroke
I
Intervention
Clopidogrel (600 mg loading dose followed by 75 mg/day) plus open-label aspirin 50–325 mg/day
C
Comparator
Matching placebo plus open-label aspirin 50–325 mg/day
O
Outcome
Composite of new ischemic vascular events — ischemic stroke, myocardial infarction, or ischemic vascular death — by 90 dayscomposite
The POINT trial is designed to evaluate the efficacy and safety of early initiation of clopidogrel plus aspirin versus aspirin alone in preventing major ischemic vascular events after a TIA or minor ischemic stroke.
Cite This Study
Johnston et al. (2013) studied this question.